1B-LSD

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = (6aR,9R)-N,N-diethyl-6-methyl-4-butanoyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide

| image = 1B-LSD Structure.svg

| width = 220

| tradename =

| legal_AU = S8

| legal_BR = F2

| legal_CA = Unscheduled

| legal_DE = NpSG

| legal_UK = PSA

| legal_US = Unscheduled (may be covered by the Federal Analogue Act if sold for human consumption)

| legal_UN = Unscheduled

| legal_US_comment =

| routes_of_administration =

| CAS_number = 2349376-12-9

| PubChem = 145875086

| ChemSpiderID = 82827098

| UNII = Y6JQX3L6LP

| C=24 | H=31 | N=3 | O=2

| smiles = CN1[C@](C2=C[C@@H](C(N(CC)CC)=O)C1)([H])CC3=CN(C(CCC)=O)C4=C3C2=CC=C4

| StdInChI = 1S/C24H31N3O2/c1-5-9-22(28)27-15-16-13-21-19(18-10-8-11-20(27)23(16)18)12-17(14-25(21)4)24(29)26(6-2)7-3/h8,10-12,15,17,21H,5-7,9,13-14H2,1-4H3/t17-,21-/m1/s1

| StdInChIKey = SVRFNPSJPIDUBC-DYESRHJHSA-N

}}

1B-LSD (N1-butyryl-lysergic acid diethylamide) is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug.{{cite journal | vauthors = Tsochatzis E, Lopes JA, Reniero F, Holland M, Åberg J, Guillou C | title = Identification of 1-Butyl-Lysergic Acid Diethylamide (1B-LSD) in Seized Blotter Paper Using an Integrated Workflow of Analytical Techniques and Chemo-Informatics | journal = Molecules | volume = 25 | issue = 3 | page = 712 | date = February 2020 | pmid = 32045999 | pmc = 7037844 | doi = 10.3390/molecules25030712 | doi-access = free }} In tests on mice it was found to be an active psychedelic, though with only around 1/7 the potency of LSD itself.{{cite journal |display-authors=6 |vauthors=Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR |date=July 2019 |title=In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures |url=http://researchonline.ljmu.ac.uk/id/eprint/9841/13/ABC-01967-2018_02_accepted.pdf |journal=Analytical and Bioanalytical Chemistry |volume=411 |issue=19 |pages=4751–4763 |doi=10.1007/s00216-018-1558-9 |pmid=30617391 |s2cid=58615418}}{{cite journal |display-authors=6 |vauthors=Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Wallach J, Halberstadt AL |date=August 2019 |title=Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD) |journal=Drug Testing and Analysis |volume=11 |issue=8 |pages=1122–1133 |doi=10.1002/dta.2613 |pmc=6899222 |pmid=31083768}}{{cite journal | vauthors = Halberstadt AL, Chatha M, Klein AK, McCorvy JD, Meyer MR, Wagmann L, Stratford A, Brandt SD | display-authors = 6 | title = Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD) | journal = Neuropharmacology | volume = 172 | pages = 107856 | date = August 2020 | pmid = 31756337 | doi = 10.1016/j.neuropharm.2019.107856 | pmc = 9191647 | s2cid = 208155327 | url = https://researchonline.ljmu.ac.uk/id/eprint/11815/1/NEUROPHARM-D-19-00561R1_accepted_uncorrected.pdf }}